Stock fact sheet · data as of
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII): fair value, margin of safety and Wheel Score
Ticker symbol DMII · Financial Services · Financial - Conglomerates · United States · Growth
Is DMII undervalued?
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) closed at 10.23 on 5 Nov 2026, close to the GLS average fair value of 9.57 (6.8% above fair value). 2 of the 5 models that produced a number sit above the price, 3 below - the market and our models roughly agree. With little margin of safety either way, the case for or against the stock rests on the quality numbers and the option premium rather than on price.
There is a wide gap between EPV (2.89) and GLS Growth (15.94). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
Ranked against every other company we cover, DMII is clearly faster-growing than it is cheap, so the nightly engine files it under Growth (value score 40, growth score 85, out of 100).
Nine valuation models for DMII
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 7.62 | -25% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 14.89 | +46% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 6.51 | -36% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 15.94 | +56% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 2.89 | -72% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.2790 | -103% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
No Piotroski health score is on file for DMII (the statements it needs were not available), so the Health part of the Wheel Score counts it at half marks - 10 of 20 - rather than marking the stock down for missing data. A GLS Moat score of 2.8/10 is a weak reading: the accounts do not show returns and margins that competitors have been unable to wear down, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC 0.9%, ROE 0.9%, ROA 0.8% - with debt at 0.00 times equity and negative free cash flow.
Drugs Made In America Acquisition II Corp. Ordinary Shares pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 10/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | - / 9 | ROIC | 0.9% |
|---|---|---|---|
| GLS Moat | 2.8 / 10 | ROE | 0.9% |
| Debt / equity | 0.00 | ROA | 0.8% |
| Free-cash-flow yield | -0.2% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 15: No options
No options are listed on Drugs Made In America Acquisition II Corp. Ordinary Shares in our nightly snapshot, so it fails the first Wheel Trade Filter (options that actually trade) (it reads 15, under 70) and is left out of every options scan; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 35k shares a day on a market cap of $651M, with a beta of 0.04 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | no listed options |
| 2 | A real business, not a gamble | Passes | Profitable over the last twelve months - not a speculative stock, fund or note |
| 3 | Below fair value | Fails | trades 7% above our fair value |
| 4 | Financially healthy | Passes | Piotroski F-score 6 or more out of 9 (a company with no score on file passes) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | no implied volatility |
| 8 | Big enough | Fails | market cap $651M (under $1.0B) |
| 9 | Not a penny stock | Passes | Share price $5 or more |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Weak | 7% above fair value | |
| Premium | Weak | no option data | |
| Moat | Weak | moat 2.8/10 | |
| Health | Fair | no Piotroski score on file - half marks | |
| Red Flags | Fair | not scored yet - half marks | |
| Option trading | Weak | no option volume data | |
| Stability | Fair | beta 0.04, $651M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for DMII in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Financial - Conglomerates
The 12 companies below are the closest to Drugs Made In America Acquisition II Corp. Ordinary Shares by market cap within the Financial - Conglomerates industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| WFHG World Financial Holding Group | 11.41 | - | - | 8No options | $725M |
| XRPN Evernorth Holdings, Inc. Class A | 10.59 | 1.15 | -824% | 14Weak | $372M |
| SAC Safeguard Acquisition Corp. | 10.12 | 1.54 | -556% | 12No options | $317M |
| DRDB Roman DBDR Acquisition Corp. II | 10.77 | 8.84 | -22% | 13No options | $248M |
| ILLU Illumination Acquisition Corp I Class A Ordinary Shares | 9.98 | 1.47 | -580% | 12No options | $236M |
| VII Viking Acquisition Corp. II | 9.80 | - | - | 12No options | $231M |
| VNME Vendome Acquisition Corporation I | 10.34 | 1.13 | -815% | 12No options | $207M |
| JONE Jones Ventures Intl Acquisition1 | 9.83 | 698.09 | +99% | 27No options | $207M |
| ETHM Dynamix Corporation | 10.97 | 29.02 | +62% | 26No options | $182M |
| BREZ Breeze Acquisition Corp. II | 10.08 | - | - | 12No options | $178M |
| RILYL BRC Group Holdings, Inc. - Depositary Shares, each representing a 1/1000th fractional interest in a share of Series B Cumulative Perpetual Preferred Stock | 7.50 | 680.27 | +99% | 27No options | $164M |
| RILYP BRC Group Holdings, Inc. | 7.25 | 660.76 | +99% | 30No options | $161M |
⚖ Compare DMII with 7 of them All Financial Services stocks →
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about DMII
Is DMII undervalued right now?
Not meaningfully: at 10.23 the stock trades within a few percent of the GLS average fair value of 9.57 (6.8% above fair value, data as of 5 Nov 2026).
What is the Wheel Score of DMII and what does it mean?
DMII has no listed options in our nightly snapshot, so it cannot be wheeled; it fails the first Wheel Trade Filter (options that actually trade), stays under 70 and is shown as "No options".
What is the GLS fair value for DMII?
9.57 per share as of 5 Nov 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Drugs Made In America Acquisition II Corp. Ordinary Shares report earnings next?
No upcoming earnings date is recorded for DMII in our calendar as of 5 Nov 2026; the Calendars page is refreshed every morning.
Does DMII have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on DMII, so the wheel strategy cannot be run on it and the Wheel Score stays under 70.